Uncontrolled bleeding and coagulopathy are associated with trauma, liver failure, obstetric conditions, and a variety of surgical circumstances, resulting in increased morbidity and mortality in the critically ill. Recently, the role of recombinant factor VIIa (rFVIIa) in the management of uncontrolled bleeding has attracted interest. rFVIIa was initially developed (and licensed) for the treatment of hemophilia. Increasingly, evidence suggests rFVIIa causes cessation of bleeding, improves coagulation markers, and reduces blood product use for treatment of severe bleeding due to other causes. The majority of evidence for nonlicensed use of rFVIIa consists of case reports. Recently, the first randomized controlled trial of rFVIIa in trauma patients reported a significant reduction in red blood cell transfusion, and a trend toward reduced mortality and critical complications. As evidence builds to support the use of rFVIIa, nurses need to be aware of the administration and safety issues of this treatment.
Skip Nav Destination
Features| April 01 2007
Recombinant Factor VIIa: Review of Current “Off License” Indications and Implications for Practice
Louise Rose, MN, RN
Louise Rose, MN, RN
Louise Rose is a Critical Care Course Coordinator in the Division of Nursing and Midwifery, RMIT University, PO Box 71, Bundoora, Victoria 3083, Australia (e-mail: email@example.com).
Search for other works by this author on:
AACN Adv Crit Care (2007) 18 (2): 141–148.
Louise Rose; Recombinant Factor VIIa: Review of Current “Off License” Indications and Implications for Practice. AACN Adv Crit Care 1 April 2007; 18 (2): 141–148. doi: https://doi.org/10.4037/15597768-2007-2006
Download citation file:
Don't already have an account? Register
AACN AccountSign In
Sign in via your InstitutionSign in via your Institution
Subscribe online and gain access to the entire archive.
Purchase short-term access on a pay-per-article or pay-per-issue basis.
$15 72 - hour single article access $30 7 - day full issue access